AstraZeneca PLC is in advanced talks to pay more than $5 billion for little-known biotech company Acerta Pharma BV and its promising cancer compound, according to people familiar with the matter.
from WSJ.com: US Business http://ift.tt/1Z4mKwr
via IFTTT
No comments:
Post a Comment